ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Otsuka Holdings Co., Ltd.

Business Summary

Otsuka Holdings Co., Ltd. engages in the management of its group companies which are in the pharmaceuticals business. It operates through the following segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products segment sells mineral water, food, and beverages. The Others segment distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded on July 8, 2008 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2021 JPYUSD
Revenue1,498.27B13,636.40M
Gross Profit1,003.24B9,130.94M
Operating income148,621M1,352.65M
Income before tax155,130M1,411.89M
Net income125,464M1,141.89M
EBITDA233,476M2,124.95M
Diluted EPS231.152.10
Dividends Per Share1000.91
Total Assets2,820.91B24,496.67M
Total liabilities775,722M6,736.32M
Total equity2,010.99B17,463.36M
Operating cash flow228,864M2,082.98M
Currency in JPYCurrency in USD

Historical Data

 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 1,239.95B 1,291.98B 1,396.24B 1,422.82B 1,498.27B
Gross Profit 817,540M 850,149M 944,943M 983,110M 1,003.24B
Operating income 112,679M 104,377M 171,547M 203,835M 148,621M
Income before tax 103,712M 109,497M 173,515M 189,988M 155,130M
Net income 112,492M 82,492M 127,152M 148,137M 125,464M
EBITDA 174,914M 163,652M 247,237M 283,258M 233,476M
Diluted EPS 206.99 151.26 231.13 272.35 231.15
Dividends Per Share 100 100 100 100 100
Total Assets 2,480.25B 2,477.36B 2,581.30B 2,627.80B 2,820.91B
Total liabilities 658,303M 745,094M 785,863M 744,371M 775,722M
Total equity 1,793.27B 1,704.49B 1,766.27B 1,852.37B 2,010.99B
Operating cash flow 102,832M 135,821M 192,634M 232,839M 228,864M
 Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021
Revenue 11,057.80M 11,698.18M 12,808.27M 13,326.26M 13,636.40M
Gross Profit 7,290.76M 7,697.63M 8,668.34M 9,207.86M 9,130.94M
Operating income 1,004.86M 945.07M 1,573.66M 1,909.13M 1,352.65M
Income before tax 924.89M 991.43M 1,591.72M 1,779.43M 1,411.89M
Net income 1,003.19M 746.92M 1,166.41M 1,387.45M 1,141.89M
EBITDA 1,559.87M 1,481.78M 2,268.00M 2,653.01M 2,124.95M
Diluted EPS 1.84 1.36 2.12 2.55 2.10
Dividends Per Share 0.89 0.90 0.91 0.93 0.91
Total Assets 22,017.36M 22,579.98M 23,752.55M 25,452.14M 24,496.67M
Total liabilities 5,843.79M 6,791.17M 7,231.31M 7,209.75M 6,736.32M
Total equity 15,919.02M 15,535.69M 16,252.79M 17,941.54M 17,463.36M
Operating cash flow 917.04M 1,229.78M 1,767.10M 2,180.78M 2,082.98M

Valuation Measures

Dec 2021
PER18.02
ROA4.60%
ROE6.49%
Operating margin9.91%
Profit margin8.37%

Key executives

  • President, CEO & Representative Director: Tatsuo Higuchi
  • Chief Financial Officer & Director: Yuko Makino
  • Executive Officer & Manager-IT Planning: Masanori Udagawa
  • Director & Vice President: Yoshiro Matsuo
  • Executive Officer & Manager-Internal Audit: Hiroki Nakayama

Shareholders

  • OTSUKA FAMILY /OTSUKA HOLDINGS/ (15.5%)
  • Nomura Asset Management Co., Ltd. (4.3%)
  • Otsuka Holdings Co., Ltd. (2.7%)
  • BlackRock Fund Advisors (2.5%)
  • Otsuka Holdings Employee Stock Ownership Plan (2.3%)
  • Daiwa Asset Management Co. Ltd. (1.9%)
  • Nikko Asset Management Co., Ltd. (1.9%)
  • The Awa Bank Ltd. (1.9%)
  • The Vanguard Group, Inc. (1.9%)
  • T. Rowe Price International Ltd. (1.4%)

Contact Details

  • Website:http://www.otsuka.com
  • Address: Shinagawa Grand Central Tower, 12/F, 2-16-4 Konan, Tokyo, 108-8241, Japan
  • Phone: +81.3.6717.1410

Related Companies

  • Otsuka Medical Devices UK Ltd.
  • Otsuka Europe Development & Commercialisation Ltd.
  • Otsuka Holdings Restricted Stock Compensation Plan
  • Otsuka Shanghai Research Institute
  • Otsuka Pharmaceutical (Switzerland) GmbH
  • Otsuka Pharmaceutical (HK) Ltd.
  • Otsuka America Foods, Inc.
  • Otsuka Pharma Scandinavia AB
  • Sichuan Otsuka Pharmaceutical Co. Ltd.
  • Otsuka (Shanghai) Foods-Safety Research & Development Co. Ltd.
  • Shanghai Otsuka Foods Co. Ltd.
  • Otsuka Pharmaceuticals (U.K.) Ltd.
  • Taiho Oncology, Inc.
  • Tianjin Otsuka Beverage Co., Ltd.
  • ReCor Medical, Inc.
  • Otsuka Medical Devices Co., Ltd.
  • Otsuka Holdingse Mployee Incentive Plan
  • Otsuka Holdings Employee Stock Ownership Plan
  • Otsuka Techno Corp.
  • Otsuka Foods Co., Ltd.
  • JIMRO Co., Ltd.
  • Nutrition & Sante' Italia SpA
  • Otsuka Pharma GmbH
  • Otsuka Packaging Ind Co. Ltd.
  • Nutrition & Sante SAS
  • Otsuka Pharmaceutical SA
  • Nardobel SAS
  • Nutrition et Soja
  • Nutrition & Sante Iberia SL
  • JO Pharma KK

Competitors

  • JW Holdings Corporation
  • Church & Dwight Co., Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • GSK plc
  • Qurient Co., Ltd.
  • Aytu BioPharma, Inc.
  • Cerevel Therapeutics Holdings Inc
  • VistaGen Therapeutics, Inc.
  • FibroGen, Inc.
  • Intra-Cellular Therapies, Inc.
  • Regulus Therapeutics Inc.
  • Rafael Holdings, Inc. Class B
  • Vaxxinity Inc Class A
  • Aptinyx Inc
  • ATAI Life Sciences N.V.
  • Axsome Therapeutics, Inc.
  • Aprea Therapeutics, Inc.
  • Kinnate Biopharma, Inc.
  • Vanda Pharmaceuticals Inc.
  • Selecta Biosciences, Inc.
  • Paik Kwang Industrial Co., Ltd.
  • Supernus Pharmaceuticals, Inc.
  • JW Pharmaceutical Corporation
  • Minerva Neurosciences Inc
  • Relay Therapeutics, Inc.
  • Theseus Pharmaceuticals, Inc.
  • ACADIA Pharmaceuticals Inc.
  • Vivoryon Therapeutics N.V.
  • Chinook Therapeutics Inc
  • Reata Pharmaceuticals, Inc. Class A
Last Updated on 18 Aug, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more